# Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

> **NCT07307053** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 600 (estimated)

## Conditions studied

- Rare Malignant Neoplasm
- Advanced Solid Tumors
- Metastatic Solid Tumors

## Interventions

- **DRUG:** BL-B01D1
- **DRUG:** VSV injection
- **DRUG:** CVL006
- **BIOLOGICAL:** IDOV-SAFE
- **BIOLOGICAL:** KXV01 TCR Lentinvivo Injection
- **BIOLOGICAL:** MT027
- **BIOLOGICAL:** QH101
- **BIOLOGICAL:** Meta10-TIL
- **BIOLOGICAL:** TAEST1901
- **BIOLOGICAL:** TC-N201
- **BIOLOGICAL:** NK510
- **DRUG:** CE120
- **DRUG:** GV20-0251
- **DRUG:** LYC001
- **DRUG:** YSCH-01
- **DRUG:** BMD006
- **DRUG:** CREPT-618
- **BIOLOGICAL:** PRG2505
- **DRUG:** IBI363
- **DRUG:** YL-201

## Key facts

- **NCT ID:** NCT07307053
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2029-01-31
- **Final completion:** 2031-01-31
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07307053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07307053, "Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07307053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*